Our experience is that misdiagnosis is relatively common – occurring in 30-40% of patients who present to us.
It is therefore likely they will have received the wrong treatments, impacting prognosis.
We know your life is worth a second opinion.
After watching our video animation scroll the page to see how Genomic Testing with ‘Next Generation Sequencing’ enables increased diagnostic accuracy.
Misdiagnosis – Our experience is common – our UK Colleagues have similar misdiagnosis observations…
Cancer Concierge in Harley Street state…
In up to 69% of cases a second opinion has resulted in a change in diagnosis, treatment recommendations or prognosis.
Study: Journal of Cancer Research & Clinical Oncology study – showed between 18-47 % patients could be left with the wrong diagnosis, wrong treatment plan, ultimately affecting prognosis.
The Grace Gawler Institute employs a Forensic Approach (no stone unturned) to ensure the patient’s original diagnosis is correct.
We help patients access advanced (genomic) oncology tests utilising ‘Next Generation Sequencing’ that precisely identifies the right drug for cancer type – thereby increasing chances of successful treatment.
We work closely with our chosen testing laboratories.
Once a correct diagnosis is established we organise referrals to innovative cancer specialists (nationally or internationally) which offer the best treatments for the particular cancer and circumstances.
We facilitate consultations or remote medical record reviews to confirm you are on the best possible treatment path, as cancer is a complex and very individualised condition.”
The following diagram from Oncofocus® (UK colleagues) is typical of new genetic tests that match the patient’s cancer with the right targeted therapy. We employ similar in Australia and Australasia.
The test works by firstly sequencing the DNA and RNA of a patient’s tumour which has been extracted from the routine histology sample used for diagnosis.
Oncofocus®’s claim for an 80% response rate is supported by our experience using high quality genomic tests. Note the poor response rate (2-16%) for therapies without testing. Oncofocus®